Analyst firms · J.P. Morgan · PCRX
J.P. Morgan PCRX price target and rating history
Pacira BioSciences Inc. (PCRX) · Health Care
J.P. Morgan rates Pacira BioSciences Inc. (PCRX) Underweight with a $10 price target, as of its latest action on Aug 12, 2024. It has published 4 rating actions on PCRX since July 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a PCRX price target in the last 12 months, the median target is $29.
- Current rating
- Underweight
- Price target
- $10
- Median target, all firms
- $29
- Actions on PCRX
- 4
J.P. Morgan price target on PCRX
Every J.P. Morgan rating on PCRX
- Aug 12, 2024
- Mar 7, 2024
- Jan 3, 2022
- Jul 26, 2021
How other firms rate PCRX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $32 | Sep 23, 2026 |
| Leerink Partners | Market Perform | $28 | Sep 9, 2026 |
| Truist Securities | Buy | $30 | Aug 17, 2026 |
| Barclays | Equal Weight | $27 | Dec 9, 2025 |
| H.C. Wainwright | Buy | Nov 17, 2025 |
Questions about J.P. Morgan and PCRX
- What is J.P. Morgan's price target for PCRX?
- J.P. Morgan's latest stated price target for Pacira BioSciences Inc. (PCRX) is $10, from its action on Aug 12, 2024.
- What is J.P. Morgan's rating on PCRX?
- J.P. Morgan rates PCRX Underweight, a bearish rating, as of Aug 12, 2024.
- When did J.P. Morgan last change its view on PCRX?
- On Aug 12, 2024, J.P. Morgan downgrades to Underweight from Overweight, price target $45 to $10.
- How does J.P. Morgan's PCRX target compare with other analysts?
- Across 4 firms with a PCRX price target in the last 12 months, the median target is $29.
More PCRX rating histories
All J.P. Morgan ratingsPCRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.